Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers-Reference-Cited by-同舟云学术

Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers

Published:2018-12-10 Issue:4 Volume:33 Page:761-765
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Vossen A.R.J.V.¹^ORCID,van der Zee H.H.¹,Davelaar N.²,Mus A.M.C.²,van Doorn M.B.A.¹,Prens E.P.¹

Affiliation:

1. Department of Dermatology Erasmus University Medical Center Rotterdam The Netherlands

2. Laboratory of Rheumatology & Dermatology Erasmus University Medical Center Rotterdam The Netherlands

Funder

AbbVie

Celgene

Novartis

Pfizer

Amgen

Biogen

UCB

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.15354

Reference17 articles.

1. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

2. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial;Vossen ARJV;J Am Acad Dermatol,2018

3. IL-1? and IFN-? induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-? up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production

4. A modified ex vivo skin organ culture system for functional studies

5. An improvement of the 2^(‐delta delta CT) method for quantitative real‐time polymerase chain reaction data analysis;Rao X;Biostat Bioinforma Biomath,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Orismilast for the treatment of mild to severe hidradenitis suppurativa: Week 16 data from OSIRIS, a Phase 2a, open‐label, single‐centre, single‐arm, dose‐finding clinical trial;Journal of the European Academy of Dermatology and Venereology;2023-12-26

2. Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS);Journal of the American Academy of Dermatology;2023-11

3. Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study;British Journal of Dermatology;2023-02-22

4. HS 3D-SeboSkin Model Enables the Preclinical Exploration of Therapeutic Candidates for Hidradenitis Suppurativa/Acne Inversa;Pharmaceutics;2023-02-12

5. Evolving utility of apremilast in dermatological disorders for off-label indications;Clinical and Experimental Dermatology;2022-12-01